[Meta-analysis Evaluating the Risk of Respiratory Tract Infections and Acute Respiratory Distress Syndrome with Glucagon-like Peptide-1 Receptor Agonists in Cardiovascular Outcome Trials: Useful Implications for the COVID-19 Pandemic]

Overview

Journal Rev Clin Esp

Specialty General Medicine

Date 2021 May 3

PMID 33935292

Authors

D Patoulias

A Boulmpou

K Imprialos

K Stavropoulos

C Papadopoulos

M Doumas

Affiliations

Soon will be listed here.

Abstract

Patients with type 2 diabetes mellitus (T2DM) are at increased risk for severe coronavirus disease 2019 (COVID-19) and related mortality. Glucagon-like peptide-1 receptor agonists (GLP-1-RAs) have significant cardiovascular and renal benefits for patients with T2DM and related comorbidities. Their anti-inflammatory properties could be beneficial in these patients. This work provides less-biased estimates regarding the risk for respiratory tract infections and acute respiratory distress syndrome by performing the first significant meta-analysis of cardiovascular outcome trials in the literature. Notably, GLP-1-RAs do not seem to increase the risk for respiratory tract infection, pneumonia, or acute respiratory distress syndrome in patients with T2DM and cardiovascular comorbidities.

References

Bornstein S, Rubino F, Khunti K, Mingrone G, Hopkins D, Birkenfeld A . Practical recommendations for the management of diabetes in patients with COVID-19. Lancet Diabetes Endocrinol. 2020; 8(6):546-550. PMC: 7180013. DOI: 10.1016/S2213-8587(20)30152-2. View

Hernandez A, Green J, Janmohamed S, DAgostino Sr R, Granger C, Jones N . Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. Lancet. 2018; 392(10157):1519-1529. DOI: 10.1016/S0140-6736(18)32261-X. View

Husain M, Birkenfeld A, Donsmark M, Dungan K, Eliaschewitz F, Franco D . Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2019; 381(9):841-851. DOI: 10.1056/NEJMoa1901118. View

Marso S, Bain S, Consoli A, Eliaschewitz F, Jodar E, Leiter L . Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2016; 375(19):1834-1844. DOI: 10.1056/NEJMoa1607141. View

Varikasuvu S, Dutt N, Thangappazham B, Varshney S . Diabetes and COVID-19: A pooled analysis related to disease severity and mortality. Prim Care Diabetes. 2020; 15(1):24-27. PMC: 7456278. DOI: 10.1016/j.pcd.2020.08.015. View

Longo M, Caruso P, Maiorino M, Bellastella G, Giugliano D, Esposito K . Treating type 2 diabetes in COVID-19 patients: the potential benefits of injective therapies. Cardiovasc Diabetol. 2020; 19(1):115. PMC: 7375203. DOI: 10.1186/s12933-020-01090-9. View

Dambha-Miller H, Albasri A, Hodgson S, Wilcox C, Khan S, Islam N . Currently prescribed drugs in the UK that could upregulate or downregulate ACE2 in COVID-19 disease: a systematic review. BMJ Open. 2020; 10(9):e040644. PMC: 7490921. DOI: 10.1136/bmjopen-2020-040644. View

Gerstein H, Colhoun H, Dagenais G, Diaz R, Lakshmanan M, Pais P . Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 2019; 394(10193):121-130. DOI: 10.1016/S0140-6736(19)31149-3. View

Holman R, Bethel M, Mentz R, Thompson V, Lokhnygina Y, Buse J . Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2017; 377(13):1228-1239. PMC: 9792409. DOI: 10.1056/NEJMoa1612917. View

10.

Barron E, Bakhai C, Kar P, Weaver A, Bradley D, Ismail H . Associations of type 1 and type 2 diabetes with COVID-19-related mortality in England: a whole-population study. Lancet Diabetes Endocrinol. 2020; 8(10):813-822. PMC: 7426088. DOI: 10.1016/S2213-8587(20)30272-2. View

11.

Marso S, Daniels G, Brown-Frandsen K, Kristensen P, Mann J, Nauck M . Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2016; 375(4):311-22. PMC: 4985288. DOI: 10.1056/NEJMoa1603827. View

12.

Buse J, Wexler D, Tsapas A, Rossing P, Mingrone G, Mathieu C . 2019 Update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2019; 43(2):487-493. PMC: 6971782. DOI: 10.2337/dci19-0066. View

13.

Pfeffer M, Claggett B, Diaz R, Dickstein K, Gerstein H, Kober L . Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome. N Engl J Med. 2015; 373(23):2247-57. DOI: 10.1056/NEJMoa1509225. View

14.

Lisco G, De Tullio A, Giagulli V, Guastamacchia E, De Pergola G, Triggiani V . Hypothesized mechanisms explaining poor prognosis in type 2 diabetes patients with COVID-19: a review. Endocrine. 2020; 70(3):441-453. PMC: 7417102. DOI: 10.1007/s12020-020-02444-9. View

15.

Holman N, Knighton P, Kar P, OKeefe J, Curley M, Weaver A . Risk factors for COVID-19-related mortality in people with type 1 and type 2 diabetes in England: a population-based cohort study. Lancet Diabetes Endocrinol. 2020; 8(10):823-833. PMC: 7426091. DOI: 10.1016/S2213-8587(20)30271-0. View